Quarterly report · Q1
3353.TEDINET S100REIO
Period2023-03-01 → 2023-05-31
Filed2023-07-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥8.7bn | 2023-03-01 → 2023-05-31 | Cons. | Net sales |
| Revenue | ¥33.9bn | 2022-03-01 → 2023-02-28 | Cons. | Net sales (5-year summary) |
| Revenue | ¥8.6bn | 2022-03-01 → 2022-05-31 | Cons. | Net sales |
| Operating income | ¥294m | 2023-03-01 → 2023-05-31 | Cons. | Operating income |
| Operating income | ¥239m | 2022-03-01 → 2022-05-31 | Cons. | Operating income |
| Ordinary income | ¥338m | 2023-03-01 → 2023-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-03-01 → 2023-02-28 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥313m | 2022-03-01 → 2022-05-31 | Cons. | Ordinary income |
| Profit before tax | ¥375m | 2023-03-01 → 2023-05-31 | Cons. | Income before income taxes |
| Profit before tax | ¥334m | 2022-03-01 → 2022-05-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥212m | 2023-03-01 → 2023-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥760m | 2022-03-01 → 2023-02-28 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥208m | 2022-03-01 → 2022-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥224m | 2023-03-01 → 2023-05-31 | Cons. | Profit loss |
| Net income | ¥213m | 2022-03-01 → 2022-05-31 | Cons. | Profit loss |
| Total assets | ¥28.1bn | at 2023-05-31 | Cons. | Assets |
| Total assets | ¥27.5bn | at 2023-02-28 | Cons. | Assets |
| Total assets | ¥28.8bn | at 2022-05-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥15.4bn | at 2023-05-31 | Cons. | Liabilities |
| Total liabilities | ¥14.9bn | at 2023-02-28 | Cons. | Liabilities |
| Net assets / equity | ¥12.7bn | at 2023-05-31 | Cons. | Net assets |
| Net assets / equity | ¥12.6bn | at 2023-02-28 | Cons. | Net assets |
| Net assets / equity | ¥12.0bn | at 2022-05-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥6.7bn | at 2023-05-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥6.4bn | at 2023-02-28 | Cons. | Cash and deposits |
| EPS (basic) | ¥56.42 | 2023-03-01 → 2023-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥202.2 | 2022-03-01 → 2023-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥55.39 | 2022-03-01 → 2022-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 43.2% | at 2023-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.8% | at 2023-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.8% | at 2022-05-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-03-01 → 2023-05-31 | −¥277m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-03-01 → 2023-05-31 | −¥277m |
| Reconciling Itemsreconciling | segment profit | 2023-03-01 → 2023-05-31 | −¥187m |
| jpcrp040300-q1r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2023-03-01 → 2023-05-31 | ¥5.9bn |
| jpcrp040300-q1r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2023-03-01 → 2023-05-31 | ¥5.9bn |
| jpcrp040300-q1r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2023-03-01 → 2023-05-31 | ¥375m |
| jpcrp040300-q1r_E03443-000Health Carereportable segment | revenue | 2023-03-01 → 2023-05-31 | ¥2.0bn |
| jpcrp040300-q1r_E03443-000Health Carereportable segment | revenue external | 2023-03-01 → 2023-05-31 | ¥2.0bn |
| jpcrp040300-q1r_E03443-000Health Carereportable segment | revenue intersegment | 2023-03-01 → 2023-05-31 | ¥150,000 |
| jpcrp040300-q1r_E03443-000Health Carereportable segment | segment profit | 2023-03-01 → 2023-05-31 | ¥50m |
| jpcrp040300-q1r_E03443-000Medical Products Wholesalereportable segment | revenue | 2023-03-01 → 2023-05-31 | ¥1.1bn |
| jpcrp040300-q1r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2023-03-01 → 2023-05-31 | ¥810m |
| jpcrp040300-q1r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2023-03-01 → 2023-05-31 | ¥275m |
| jpcrp040300-q1r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2023-03-01 → 2023-05-31 | ¥23m |
| jpcrp040300-q1r_E03443-000Real Estatereportable segment | revenue | 2023-03-01 → 2023-05-31 | ¥47m |
| jpcrp040300-q1r_E03443-000Real Estatereportable segment | revenue external | 2023-03-01 → 2023-05-31 | ¥46m |
| jpcrp040300-q1r_E03443-000Real Estatereportable segment | revenue intersegment | 2023-03-01 → 2023-05-31 | ¥1m |
| jpcrp040300-q1r_E03443-000Real Estatereportable segment | segment profit | 2023-03-01 → 2023-05-31 | ¥34m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-03-01 → 2023-05-31 | ¥9.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-03-01 → 2023-05-31 | ¥8.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-03-01 → 2023-05-31 | ¥277m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-03-01 → 2023-05-31 | ¥481m |
| Reconciling Itemsreconciling | revenue | 2022-03-01 → 2022-05-31 | −¥253m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-03-01 → 2022-05-31 | −¥253m |
| Reconciling Itemsreconciling | segment profit | 2022-03-01 → 2022-05-31 | −¥189m |
| jpcrp040300-q1r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2022-03-01 → 2022-05-31 | ¥5.9bn |
| jpcrp040300-q1r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2022-03-01 → 2022-05-31 | ¥5.9bn |
| jpcrp040300-q1r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2022-03-01 → 2022-05-31 | ¥363m |
| jpcrp040300-q1r_E03443-000Health Carereportable segment | revenue | 2022-03-01 → 2022-05-31 | ¥1.9bn |
| jpcrp040300-q1r_E03443-000Health Carereportable segment | revenue external | 2022-03-01 → 2022-05-31 | ¥1.9bn |
| jpcrp040300-q1r_E03443-000Health Carereportable segment | revenue intersegment | 2022-03-01 → 2022-05-31 | ¥150,000 |
| jpcrp040300-q1r_E03443-000Health Carereportable segment | segment profit | 2022-03-01 → 2022-05-31 | ¥19m |
| jpcrp040300-q1r_E03443-000Medical Products Wholesalereportable segment | revenue | 2022-03-01 → 2022-05-31 | ¥946m |
| jpcrp040300-q1r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2022-03-01 → 2022-05-31 | ¥694m |
| jpcrp040300-q1r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2022-03-01 → 2022-05-31 | ¥252m |
| jpcrp040300-q1r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2022-03-01 → 2022-05-31 | ¥16m |
| jpcrp040300-q1r_E03443-000Real Estatereportable segment | revenue | 2022-03-01 → 2022-05-31 | ¥49m |
| jpcrp040300-q1r_E03443-000Real Estatereportable segment | revenue external | 2022-03-01 → 2022-05-31 | ¥49m |
| jpcrp040300-q1r_E03443-000Real Estatereportable segment | revenue intersegment | 2022-03-01 → 2022-05-31 | ¥381,000 |
| jpcrp040300-q1r_E03443-000Real Estatereportable segment | segment profit | 2022-03-01 → 2022-05-31 | ¥30m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-03-01 → 2022-05-31 | ¥8.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-03-01 → 2022-05-31 | ¥8.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-03-01 → 2022-05-31 | ¥253m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-03-01 → 2022-05-31 | ¥428m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 355
| Item | Context | Value | Unit |
|---|---|---|---|
| Profit loss | Prior1YTDDuration | 213087000 | JPY |
| Profit loss | CurrentYTDDuration | 223900000 | JPY |
| Valuation difference on available for sale securities net of tax oci | Prior1YTDDuration | -51814000 | JPY |
| Valuation difference on available for sale securities net of tax oci | CurrentYTDDuration | -54623000 | JPY |
| Remeasurements of defined benefit plans net of tax oci | Prior1YTDDuration | 323000 | JPY |
| Remeasurements of defined benefit plans net of tax oci | CurrentYTDDuration | -1267000 | JPY |
| Other comprehensive income | Prior1YTDDuration | -51490000 | JPY |
| Other comprehensive income | CurrentYTDDuration | -55890000 | JPY |
| Comprehensive income | Prior1YTDDuration | 161596000 | JPY |
| Comprehensive income | CurrentYTDDuration | 168010000 | JPY |
| Comprehensive income attributable to owners of the parent | Prior1YTDDuration | 156568000 | JPY |
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | 156072000 | JPY |
| Comprehensive income attributable to non controlling interests | Prior1YTDDuration | 5028000 | JPY |
| Comprehensive income attributable to non controlling interests | CurrentYTDDuration | 11937000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E03443-000DispensingPharmacyReportableSegmentsMember | 5872054000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E03443-000HealthCareReportableSegmentsMember | 1948918000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E03443-000MedicalProductsWholesaleReportableSegmentsMember | 694022000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E03443-000RealEstateReportableSegmentsMember | 48679000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 8563675000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 8563675000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E03443-000DispensingPharmacyReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E03443-000HealthCareReportableSegmentsMember | 150000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E03443-000MedicalProductsWholesaleReportableSegmentsMember | 252158000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E03443-000RealEstateReportableSegmentsMember | 381000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 252689000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -252689000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E03443-000DispensingPharmacyReportableSegmentsMember | 5872054000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E03443-000HealthCareReportableSegmentsMember | 1949068000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E03443-000MedicalProductsWholesaleReportableSegmentsMember | 946180000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E03443-000RealEstateReportableSegmentsMember | 49060000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 8816365000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -252689000 | JPY |
| Net sales | Prior1YTDDuration | 8563675000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E03443-000DispensingPharmacyReportableSegmentsMember | 363222000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E03443-000HealthCareReportableSegmentsMember | 18808000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E03443-000MedicalProductsWholesaleReportableSegmentsMember | 16315000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E03443-000RealEstateReportableSegmentsMember | 29700000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 428047000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -188995000 | JPY |
| Operating income | Prior1YTDDuration | 239051000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E03443-000DispensingPharmacyReportableSegmentsMember | 5910452000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E03443-000HealthCareReportableSegmentsMember | 1955093000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E03443-000MedicalProductsWholesaleReportableSegmentsMember | 810432000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E03443-000RealEstateReportableSegmentsMember | 45974000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 8721952000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 8721952000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E03443-000DispensingPharmacyReportableSegmentsMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |